Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection
Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection
复制标题
对于仅且主要是EBV感染的B淋巴细胞的EBV-HLH，含利妥昔单抗的免疫化疗方案可有效消除EBV
DOI：
10.1016/j.intimp.2021.107606
复制
发表时间：
2021-04-05
影响因子：
5.6
通讯作者：
Wang, Zhao
中科院分区：
文献类型：
--
作者：
Meng, Guang-Qiang;Wang, Jing-Shi;Wang, Zhao
EB病毒相关噬血细胞性淋巴组织细胞增生症（EBV-HLH）患者预后不良。本研究调查了含利妥昔单抗的免疫化疗方案对EBVHLH的疗效。在这项研究中，15例患者接受了含利妥昔单抗的治疗方案。观察两组治疗效果及不良反应。在10例患者中，EBV DNA在第一疗程后变为阴性。10例EBV感染的淋巴细胞类型均为B细胞型，且以B细胞型为主。其余5例患者治疗前后外周血单个核细胞（PBMC）EBVDNA含量差异无统计学意义（P = 0.111）。此外，在这5例患者中，EB病毒主要感染T细胞和NK细胞。5例外周血单个核细胞EBVDNA无明显下降的患者中，2例接受异基因造血干细胞移植后EBVDNA转阴。本研究表明，含利妥昔单抗的方案是治疗仅有且主要是B淋巴细胞被EBV感染的EBV-HLH的有效疗法，尤其是对于消除EBV。
Patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) have a poor prognosis. This study investigated the efficacy of rituximab-containing immuno-chemotherapy regimens for EBVHLH. In this study, 15 patients were treated with rituximab-containing regimens. The treatment efficacy and adverse events were evaluated. In 10 patients, EBV DNA became negative after the first course of treatment. The lymphocyte types infected by EBV in the 10 patients were only infected with B cells and mainly infected with B cells. In the other 5 patients, the EBV DNA of peripheral blood mononuclear cells (PBMC) before and after treatment with the regimens had no statistical difference (P = 0.111). In addition, in these 5 patients, EBV mainly infected T and NK cells. Among the 5 patients without a significant decline in EBV DNA of PBMC, 2 patients received allogeneic hematopoietic stem cell transplantation and turned negative for EBV DNA. This study suggests that rituximab-containing regimens are effective therapy for EBV-HLH with only and mainly B lymphocytes infected by EBV, especially for eliminating EBV.